Loading...
•
Mar 31, 2022
Zai Lab Q1 2022 Earnings Report
Reported solid financial results for the first quarter of 2022, driven by commercial growth and pipeline advancement.
Key Takeaways
Zai Lab reported total revenues of $46.7 million for the first quarter of 2022, compared to $20.1 million for the same period in 2021. The net loss was $82.4 million, compared to $232.9 million for the same period in 2021. The company continues to advance its pipeline and commercial operations.
Total revenues reached $46.7 million, a significant increase from $20.1 million in the same period last year.
Product revenues increased for ZEJULA, Optune, QINLOCK and NUZYRA.
R&D expenses decreased due to no upfront payments for new licensing agreements.
Zai Lab continues to progress toward achieving strategic priorities, including filing the NDA for efgartigimod in China in mid-2022.
Zai Lab
Zai Lab
Zai Lab Revenue by Segment
Revenue by Segment
ZEJULA Revenue
CapyFin.comNUZYRA Revenue
CapyFin.com Forward Guidance
Zai Lab anticipates several milestones in 2022, including regulatory submissions, clinical trial initiations, and data readouts for its key programs.
Positive Outlook
- Filing the NDA for efgartigimod in China in mid-2022.
- Initiation of a registrational study for bemarituzumab in first-line gastric cancer in Greater China.
- Topline data readout for KarXT from its Phase 3 EMERGENT-2 trial in the third quarter of 2022.
- Continued investment in R&D to advance our proprietary pipeline with global rights, including moving ZL-1102 into full global development.
- Seek National Reimbursement Drug List (NRDL) inclusion for CABP and ABSSSI indications.
Challenges Ahead
- Challenges due to the COVID situation in certain regions in China.
- Current macro and geopolitical headwinds.
- Uncertainties and risks associated with drug development and commercialization.
- Potential delays in regulatory approvals.
- The company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in its forward-looking statements.
Revenue & Expenses
Visualization of income flow from segment revenue to net income